FDA Approves Radioembolization Therapy for Unresectable Hepatocellular Carcinoma

The use of SIR-Spheres achieved a 98.5 percent overall response rate in the treatment of hepatocellular carcinoma in a recent prospective multicenter trial.

Read the full article on diagnosticimaging.com